

Radoslaw Kaczmarek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1477658/publications.pdf>

Version: 2024-02-01

45
papers

530
citations

686830

13
h-index

713013

21
g-index

50
all docs

50
docs citations

50
times ranked

673
citing authors

#	ARTICLE	IF	CITATIONS
1	Ludwik Hirszfeld: A pioneer of transfusion and immunology during the world wars and beyond. <i>Vox Sanguinis</i> , 2022, 117, 467-475.	0.7	4
2	Treatment-induced hemophilic thrombosis?. <i>Molecular Therapy</i> , 2022, 30, 505-506.	3.7	7
3	Gene therapy "are we ready now?. <i>Haemophilia</i> , 2022, 28, 35-43.	1.0	5
4	One of the two N-glycans on the human Gb3/CD77 synthase is essential for its activity and allosterically regulates its function. <i>Biochemical and Biophysical Research Communications</i> , 2022, 617, 36-41.	1.0	3
5	Management of COVID-19-associated coagulopathy in persons with haemophilia. <i>Haemophilia</i> , 2021, 27, 41-48.	1.0	14
6	Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry. <i>Journal of Biological Chemistry</i> , 2021, 296, 100299.	1.6	9
7	Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. <i>Haemophilia</i> , 2021, 27, 515-518.	1.0	9
8	B cell-activating factor modulates the factor VIII immune response in hemophilia A. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	10
9	Missing the sweet spot: one of the two N-glycans on human Gb3/CD77 synthase is expendable. <i>Glycobiology</i> , 2021, 31, 1145-1162.	1.3	1
10	Two Paralogous Gb3/CD77 Synthases in Birds Show Different Preferences for Their Glycoprotein and Glycosphingolipid Substrates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9761.	1.8	0
11	Helper T Cell Response to Factor VIII <i>In Vivo</i> Requires Several Anatomically Distinct Types of Antigen Presenting Cells. <i>Blood</i> , 2021, 138, 440-440.	0.6	0
12	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENER-1 Phase 3 Trial. <i>Blood</i> , 2021, 138, 3972-3972.	0.6	0
13	Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration. <i>Blood</i> , 2021, 138, 3194-3194.	0.6	0
14	Eliminating Panglossian thinking in development of AAV therapeutics. <i>Molecular Therapy</i> , 2021, 29, 3325-3327.	3.7	12
15	A Molecular Revolution in the Treatment of Hemophilia. <i>Molecular Therapy</i> , 2020, 28, 997-1015.	3.7	66
16	Professor Elwira Lisowska Celebrates Her 90th Birthday. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 1.	1.0	2
17	Curing Hemophilia: Repeated Treatments versus a One-Off Fix. <i>Molecular Therapy</i> , 2020, 28, 1229-1230.	3.7	1
18	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. <i>Haemophilia</i> , 2020, 26, 931-933.	1.0	24

#	ARTICLE	IF	CITATIONS
19	How glycosylation affects glycosylation: the role of N-glycans in glycosyltransferase activity. <i>Glycobiology</i> , 2020, 30, 941-969.	1.3	37
20	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. <i>Haemophilia</i> , 2020, 26, 443-449.	1.0	15
21	Alternative Approaches to Oral Tolerance Induction to Factor FVIII. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
22	Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8 ⁺ and Plasmacytoid Dendritic Cells <i>in Route</i> to Enhancing FVIII Inhibitor Formation. <i>Blood</i> , 2020, 136, 1-1.	0.6	1
23	Safety and efficacy of emicizumab and other novel agents in newborns and infants. <i>Haemophilia</i> , 2019, 25, e334-e335.	1.0	16
24	Erythrocyte glycoporphins as receptors for Plasmodium merozoites. <i>Parasites and Vectors</i> , 2019, 12, 317.	1.0	43
25	The patient's view on rare disease trial design – a qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 31.	1.2	34
26	Toll-like Receptor 9 Activation Accelerates Inhibitor Formation in Response to Factor VIII. <i>Blood</i> , 2019, 134, 1113-1113.	0.6	0
27	The Gerbich blood group system: old knowledge, new importance. <i>Transfusion Medicine Reviews</i> , 2018, 32, 111-116.	0.9	16
28	The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. <i>Health Policy</i> , 2018, 122, 1287-1294.	1.4	11
29	Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system. <i>PLoS ONE</i> , 2018, 13, e0196627.	1.1	11
30	RT-qPCR analysis of human melanoma progression-related genes – A novel workflow for selection and validation of candidate reference genes. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 101, 12-18.	1.2	6
31	Do adventitious viruses carried by insect cell lines producing AAV vectors pose a safety risk in gene therapy?. <i>Haemophilia</i> , 2018, 24, 843-844.	1.0	5
32	Hepatitis C and bleeding disorders in Europe. <i>The Journal of Haemophilia Practice</i> , 2018, 5, 50-65.	0.2	0
33	CD1: A Singed Cat of the Three Antigen Presentation Systems. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 201-214.	1.0	9
34	Plasmodium reichenowi EBA-140 merozoite ligand binds to glycoporphin D on chimpanzee red blood cells, shedding new light on origins of Plasmodium falciparum. <i>Parasites and Vectors</i> , 2017, 10, 554.	1.0	6
35	Evaluation of an amino acid residue critical for the specificity and activity of human Gb3/CD77 synthase. <i>Glycoconjugate Journal</i> , 2016, 33, 963-973.	1.4	11
36	Baculovirus-expressed Plasmodium reichenowi EBA-140 merozoite ligand is host specific. <i>Parasitology International</i> , 2016, 65, 708-714.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Human Gb3/CD77 synthase reveals specificity toward two or four different acceptors depending on amino acid at position 211, creating Pk, P1 and NOR blood group antigens. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 168-174.	1.0	20
38	Can mutations in the gene encoding transcription factor EKLF (Erythroid KrÄppel-Like Factor) protect us against infectious and parasitic diseases?. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 1068-1086.	0.1	1
39	The Baculovirus-Expressed Binding Region of Plasmodium falciparum EBA-140 Ligand and Its Glycophorin C Binding Specificity. <i>PLoS ONE</i> , 2015, 10, e0115437.	1.1	19
40	Studies of a Murine Monoclonal Antibody Directed against DARC: Reappraisal of Its Specificity. <i>PLoS ONE</i> , 2015, 10, e0116472.	1.1	6
41	P1PK, GLOB, and FORS Blood Group Systems and GLOB Collection: Biochemical and Clinical Aspects. Do We Understand It All Yet?. <i>Transfusion Medicine Reviews</i> , 2014, 28, 126-136.	0.9	33
42	Genetyczne podstawy syntezy cukrowych antygenów grupowych krwi. <i>Acta Haematologica Polonica</i> , 2013, 44, 251-259.	0.1	2
43	A Single Point Mutation in the Gene Encoding Gb3/CD77 Synthase Causes a Rare Inherited Polyagglutination Syndrome. <i>Journal of Biological Chemistry</i> , 2012, 287, 38220-38230.	1.6	40
44	Bacterially expressed truncated F2 domain of Plasmodium falciparum EBA-140 antigen can bind to human erythrocytes.. <i>Acta Biochimica Polonica</i> , 2012, 59, .	0.3	5
45	Bacterially expressed truncated F2 domain of Plasmodium falciparum EBA-140 antigen can bind to human erythrocytes. <i>Acta Biochimica Polonica</i> , 2012, 59, 685-91.	0.3	2